FDA Warning Letter: Wholesale Distributor Enforcement 2025

FDA Warning Letter Issued to East CK Trading Inc. — Wholesale Distributor Compliance Enforcement

On January 9, 2025, FDA issued a warning letter to East CK Trading Inc., a California-based wholesale drug distributor, for violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) related to drug distribution without proper state licensure. The enforcement action reflects FDA's ongoing scrutiny of wholesale distributor compliance infrastructure and its coordination with state boards of pharmacy to identify unlicensed distribution activity.

Regulatory Context

Under 21 U.S.C. 353(e)(1), wholesale drug distributors must be licensed by the state in which they are located and by each state into which they distribute drugs. This requirement applies to all entities engaged in wholesale distribution as defined under 21 U.S.C. 360eee(27) — the purchase or other acquisition of prescription drugs for resale to entities other than consumers.

FDA coordinates enforcement with state boards of pharmacy through the National Association of Boards of Pharmacy (NABP). State licensure is a prerequisite for participation in the Drug Supply Chain Security Act (DSCSA) transaction verification system, which requires all trading partners to exchange authorized transaction history (ATH), transaction information (TI), and transaction statements (TS) for prescription drug transactions. Entities operating without state licensure are automatically excluded from DSCSA-compliant supply chains.

Violations Cited

The warning letter identifies three primary violations:

1. Distribution without state licensure — East CK Trading Inc. distributed prescription drugs into multiple states without holding active wholesale drug distributor licenses in those jurisdictions. FDA cited specific shipments documented through transaction records and shipping manifests.

1. Failure to maintain pedigree documentation — The entity did not maintain complete transaction history for distributed products, in violation of 21 U.S.C. 360eee-1. This prevented downstream trading partners from verifying the chain of custody for received products.

1. Distribution of unapproved products — The warning letter cites distribution of prescription drugs labeled in a foreign language without FDA-approved labeling, constituting introduction of unapproved new drugs into interstate commerce under 21 U.S.C. 355(a).

FDA requested written response within 15 working days detailing corrective actions, including cessation of unlicensed distribution, implementation of licensure verification procedures, and remediation of pedigree documentation gaps.

Operational Implications for Wholesale Distributors

This enforcement action reinforces FDA's position that state licensure is not optional administrative paperwork — it is a gatekeeping requirement for supply chain participation. Wholesale distributors should assess three operational areas:

State licensure coverage — Entities must hold active licenses in every state where they physically ship product, not just their headquarters state. Multi-state distributors should maintain a licensure matrix documenting coverage by jurisdiction and renewal dates.

Trading partner verification — Downstream entities (pharmacies, hospitals, repackagers) bear responsibility for verifying that their wholesale suppliers hold valid licenses under DSCSA requirements. A supplier operating without licensure exposes the buyer to regulatory action. Procurement teams should implement pre-qualification checks against state board of pharmacy databases.

Transaction documentation — Pedigree gaps create liability for both the distributor and the receiving entity. DSCSA mandates electronic exchange of TI/TH/TS by November 27, 2025, but paper-based systems must still maintain complete chain of custody. Entities relying on manual processes should audit transaction files for completeness before the electronic enforcement date.

The warning letter does not specify whether FDA will pursue consent decree, injunction, or civil monetary penalties. However, continued operation without licensure after notice constitutes knowing violation, escalating potential enforcement severity under 21 U.S.C. 333.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors tracked in ColdChainCheck's directory, state licensure coverage is the single largest determinant of compliance scores. The scoring model allocates 25 points (25% of total score) to state licensure breadth, reflecting the regulatory reality demonstrated by this warning letter: unlicensed distribution is disqualifying.

State licensure verification gaps remain widespread across the industry. The average compliance score of 51/100 indicates that most entities in the directory have partial but incomplete compliance signals. Only 28 entities (2.2%) hold "Excellent" scores (76-100 points), meaning fewer than 3% of tracked distributors demonstrate comprehensive cross-jurisdiction licensure, NABP accreditation, FDA registration, and clean enforcement records. The 919 entities (72%) in the "Fair" tier (26-50 points) typically hold licenses in 10-25 states — adequate for regional operations but insufficient for national distribution claims.

NABP accreditation remains concentrated among large distributors. Only 63 entities in the directory hold Verified-Accredited Wholesale Distributors (VAWD) accreditation. NABP's accreditation process includes independent verification of state licensure status across all claimed jurisdictions, providing a third-party validation signal that procurement teams can use to reduce due diligence burden. Entities without VAWD accreditation require manual verification against each state board of pharmacy database.

Enforcement action visibility matters for trading partner qualification. ColdChainCheck tracks 73 entities with FDA recalls or warning letters on record. This represents 5.7% of the directory but captures only publicly disclosed enforcement. The East CK Trading Inc. warning letter will be added to the entity's compliance profile upon database update, permanently flagging the enforcement history for procurement teams conducting pre-qualification checks.

Recommended Actions for Compliance Officers

• Verify supplier licensure across all ship-to states — Use ColdChainCheck's state filter to identify which distributors hold licenses in your jurisdiction. Cross-reference against your approved vendor list. Suppliers claiming "nationwide coverage" should demonstrate licenses in all 50 states plus DC.

• Prioritize NABP-accredited suppliers in RFPs — VAWD accreditation provides independent verification of licensure status. Filter the directory by accreditation status to identify pre-verified entities.

• Audit transaction documentation completeness — The warning letter cites pedigree gaps as a distinct violation. Review your incoming TI/TH/TS records for the past 6 months. Missing transaction statements from any supplier indicate potential compliance exposure for your organization, not just the supplier.

• Monitor enforcement updates — ColdChainCheck updates entity profiles when FDA publishes warning letters or recall notices. Subscribe to state board of pharmacy email alerts for jurisdictions where you operate to receive real-time licensure status changes.

ColdChainCheck tracks state licensure, NABP accreditation, FDA registration, and enforcement actions across all entities in the directory. For methodology documentation and score calculation breakdowns, see /guides/compliance-score-methodology.

Disclaimer: This article is informational only and does not constitute legal or regulatory advice. Entities should verify all compliance requirements with qualified legal counsel and the relevant regulatory authorities.